E
Elicio Therapeutics
Transforming the lives of patients and their families by re-engineering the body’s immune response to cancer
About Elicio Therapeutics
Elicio Therapeutics is a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies. The company leverages the natural power of the lymph nodes to enhance the immune system's response against tumors. Elicio's targeted delivery approach aims to generate robust immune responses by activating and amplifying cancer-fighting T cells, potentially enabling patients to combat aggressive cancers more effectively. The company operates in the immuno-oncology market, serving patients battling various forms of cancer. Elicio's business model revolves around the research, development, and clinical trials of its proprietary therapies, with revenue generated through partnerships, grants, and future commercialization of successful treatments. The company's mission is to revolutionize cancer treatment by providing patients with the best possible outcomes through cutting-edge immunotherapy solutions.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2012
- Headquarters
- Boston, United States
- Listing
- IPO 2023
- Employees
- 47
- Open positions
- None listed
- Dealroom signal
- 80.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Vaccines, Immune System, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jan 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jul 2026 | $15M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Jan 2025 | $10M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$35M | — |
| 2025 | $0 | — | −$35M | — |
| 2024 | $0 | — | −$47M | — |
| 2023 | $0 | — | −$34M | — |
| 2022 | $0 | — | −$23M | — |
| 2021 | $0 | — | −$25M | — |
| 2020 | $0 | — | −$16M | — |
Growth signals
Latest recorded traffic for Elicio Therapeutics is 7.4K monthly website visits, down 38.3% over the last three months. Elicio Therapeutics's team grew 9.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Gastro-Intestinal Research Foundation
Series A3 investors entered at this stage
Clal Biotechnology Industries
Livzon Pharmaceutical Group- GKGKCC
Series B and later1 investor entered at this stage
Angion Biomedica
Other known investors3 additional known investors
Keio University
Massachusetts Institute of Technology
The University of Tokyo
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Elicio Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Elicio Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.